/
ANVS
$1.82-$0.01 (-0.56%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$76.6M
43M shares
52-week range
$1.54 – $5.50
7% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
CS
Change$-38.22
Annovis Bio, Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
www.annovisbio.com- Employees
- 7
- IPO / List date
- Jan 29, 2020
- HQ
- MALVERN, PA
Held by traders on TradeandTell
No one on the platform currently holds ANVS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 347,600 | $775.1K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ANVS yet.
